14,700 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Orbimed Advisors LLC

Key Points

• Orbimed Advisors acquired 14,700 Regeneron shares worth approximately $11.36 million, while institutional investors collectively own 83.31% of the company.
• Regeneron beat quarterly expectations with earnings of $9.47 per share and revenue of $3.61 billion, up 19% year over year; analysts maintain a “Moderate Buy” consensus with an average price target of $787.88.
• The company faces ongoing securities-class-action lawsuits alleging investors were misled about clinical-trial protocols and risks, following a reported selloff and substantial market-cap loss.

Orbimed Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,700 shares of the biopharmaceutical company's stock, valued at approximately $11,358,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. WPG Advisers LLC grew its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Kemnay Advisory Services Inc. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Finally, Entrust Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals NASDAQ: REGN Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $656.01 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The stock's 50-day moving average is $635.78 and its two-hundred day moving average is $714.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a market cap of $69.35 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts' consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts' expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business's quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.22 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company's stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company's stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a research report on Monday, May 18th. Citigroup lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the company from $900.00 to $700.00 in a report on Monday, May 18th. Cantor Fitzgerald lowered their price target on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an "overweight" rating for the company in a research note on Monday, July 6th. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Finally, Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a "buy" rating on the stock in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $787.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.